Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07294027

ICSI Versus Conventional IVF in Couples With Unexplained Infertility

This multicenter, open-label, parallel-group, randomized controlled trial aims to compare the live birth rate, fertilization outcomes, other pregnancy outcomes and safety between ICSI and conventional IVF among couples with unexplained infertility in China.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

20 year–38 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, Beijing Municipality, China

Loading trial locations.

About this study

A multicenter, large-scale, randomized controlled clinical trial will enroll 848 couples with unexplained infertility undergoing their first cycle of IVF or ICSI. The study will recruit participants from 6 Reproductive Medical Centers across mainland China. The participation in this study will be approximately 1 years with a total of 9 visits from controlled ovarian hyperstimulation, pregnancy to delivery. On the day of oocyte retrieval, eligible participants will be allocated to either the ICSI group or the IVF group in a 1:1 ratio. All participants will be randomized through block randomization, and each center will enroll participants using a competitive enrollment method.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged 20-38 years
  • 18.5 < BMI < 24kg/m2
  • Couples diagnosed with primary unexplained infertility:
  • Regular menses or confirmed ovulation;
  • Normal ovarian reserve;
  • Patent fallopian tubes;
  • Normal uterus and cervix;
  • Normal endocrine profile;
  • Semen analysis meeting WHO 6th edition criteria
  • Normal karyotypes in both partners, no family history of genetic disorders
  • First IVF/ICSI cycle
  • Received GnRH agonist protocol or GnRH antagonist protocol
  • Willing to provide informed consent and comply with follow-up

Exclusion criteria

  • Preimplantation genetic testing (PGT) cycles
  • In vitro maturation (IVM) cycles
  • Using donor sperm/oocyte
  • Using frozen sperm/oocyte
  • <5 oocytes retrieved
  • Abnormal semen parameters on the day of oocyte retrieval
  • High risk of tubal pathology or endometriosis without laparoscopic exclusion
  • Untreated or poorly controlled endocrine disorders
  • Abnormal immune related examinations
  • Major organ/system disorders (cardiac, hepatic, renal, oncologic, hematologic, psychiatric, etc.)
  • Concurrent participation in other clinical trials.

Treatment and study plan

ICSI

Procedure

Insemination will be performed by using ICSI, 2 hours after oocyte retrieval. COCs will be stripped by using hyaluronidase. Only matured oocytes (MII stage) will be injected. Fertilization check will be performed at period of 16-18 hours after injection.

Other standard assisted reproductive treatments are similar and parallel between two groups.

IVF

Procedure

Insemination will be performed by using conventional IVF, 2-4 hours after oocyte retrieval. Collected COCs will be inseminated (1-5×105 sperm/ml) and cultured overnight in culture medium. Fertilization check will be performed at period of 16-18 hours after insemination.

If the IVF group experiences total fertilization failure or a fertilization rate of less than 25%, late rescue ICSI (Late-RICSI) will be performed on all MII stage oocytes using semen retained on the day of egg retrieval. The injection method is same as standard ICSI.

Other standard assisted reproductive treatments are similar and parallel between two groups.

Primary outcomes

  1. Live birth rate after the first embryo transfer cycle

    Time frame: At birth

    Live birth is defined as the birth of at least one newborn after 24 weeks' gestation that exhibits any sign of life (twin will be a single count).

Secondary outcomes

  1. Cumulative ongoing pregnancy rate within one year

    Time frame: At 12 weeks of gestation; At 12 months after randomization

    Achieving ongoing pregnancy within 12 months after randomization, regardless of the number of embryo transfers performed (limited to embryos obtained in the current study).

    Ongoing pregnancy refers to the presence of a gestational sac and fetal heart beat after 12 weeks of gestation.

  2. Number of retrieved oocyte

    Time frame: 2 hours after oocyte retrieval

    Number of oocyte obtained on the day of oocyte retrieval

  3. MII rate

    Time frame: 2 hours after oocyte retrieval

    [Only in ICSI group] The proportion of MII oocytes to the total number of retrieved oocytes.

  4. Fertilization rate per oocyte inseminated/injected

    Time frame: At 16-18 hours after insemination or injection

    The proportion of fertilized oocytes to inseminated oocytes (IVF group) / injected oocytes (ICSI group).

  5. Fertilization rate per oocyte retrieved

    Time frame: At 16-18 hours after insemination or injection

    The proportion of fertilized oocytes to the total number of retrieved oocytes.

  6. Normal fertilization rate

    Time frame: At 16-18 hours after insemination or injection

    Normal fertilization is defined as the appearance of 2PN

  7. Abnormal fertilization rate

    Time frame: At 16-18 hours after insemination or injection

    Abnormal fertilization is defined as the appearance of 1PN or ≥3PN

  8. Degeneration rate of ICSI oocytes

    Time frame: At 16-18 hours after injection

    [Only in ICSI group] The proportion of oocytes that undergo degeneration assessed on Day 2 among all oocytes receiving ICSI.

  9. Cleavage rate

    Time frame: At 16-18 hours after insemination or injection

    The proportion of normal cleavage observed on Day 2 in normally fertilized oocytes

  10. Day 2 embryo formation rate

    Time frame: 2 days after oocyte retrieval

    The proportion of 4-cell stage embryos formed on Day 2 compared to normal fertilized oocytes.

  11. Day 3 embryo formation rate

    Time frame: 3 days after oocyte retrieval

    The proportion of 8-cell stage embryos formed on Day 3 compared to normal fertilized oocytes.

  12. Good quality embryo rate on Day 3

    Time frame: 3 days after oocyte retrieval

    The proportion of I-II grade embryos with 6-10 cells on Day 3 compared to normal fertilized oocytes, according to Peter's scoring criteria.

  13. Blastocyst formation rate

    Time frame: 6 days after oocyte retrieval

    The proportion of the number of blastocysts formed to the number of embryos undergoing blastocyst culture.

  14. Good quality blastocyst formation rate

    Time frame: 6 days after oocyte retrieval

    The proportion of the number of blastocysts classified as 3BB or higher grade (according to Gardner scoring system) to the number of embryos undergoing blastocyst culture.

  15. Good quality blastocyst rate

    Time frame: 6 days after oocyte retrieval

    The proportion of good quality blastocysts to the total number of blastocysts.

  16. Number of available blastocyst

    Time frame: 6 days after oocyte retrieval

    Number of blastocysts of BC, CB grade and above, according to the Gardner scoring system.

  17. Number of available embryo

    Time frame: 6 days after oocyte retrieval

    The total number of embryos that can be utilized for transplantation or cryopreservation.

  18. Total fertilization failure rate

    Time frame: At 16-18 hours after insemination or injection

    Total fertilisation failure rate is defined as the absence of any zygotes with 2PN

  19. Cycle cancellation rate

    Time frame: 6 days after oocyte retrieval

    The proportion of cycles with total fertilization failure or no available embryo to all oocyte retrieval cycles.

  20. Moderate/severe ovarian hyperstimulation syndrome (OHSS)

    Time frame: At 10days after trigger; At 14 days after embryo transfer

    The exaggerated systemic response to ovarian stimulation. It is classified into mild, moderate, and severe based on the degree of bloating, ovarian volume enlargement, and respiratory, hemodynamic, and metabolic complications.

  21. Positive pregnancy rate

    Time frame: 10-14 days after embryo transfer; At 12 months after randomization

    Positive pregnancy test is defined as a serum human chorionic gonadotropin level greater than 10mIU/mL after embryo transfer.

  22. Clinical pregnancy rate

    Time frame: 30 days after embryo transfer

    Clinical pregnancy is defined as ultrasound detection of at least one gestational sac or other clear pregnancy manifestations under ultrasound (including clear ectopic pregnancy).

  23. Implantation rate

    Time frame: 30 days after embryo transfer; At 12 months after randomization

    Implantation rate is defined as the number of gestational sacs per number of embryos transferred.

  24. Ongoing pregnancy rate

    Time frame: At 12 weeks of gestation; At 12 months after randomization

    Ongoing pregnancy refers to the presence of a gestational sac and fetal heart beat after 12 weeks of gestation.

  25. Ectopic pregnancy

    Time frame: 30 days after embryo transfer; At 12 months after randomization

    Ectopic pregnancy is defined as the presence of the gestational sac outside the uterine cavity detected by ultrasound.

  26. Multiple pregnancy rate

    Time frame: 30 days after oocyte retrieval; At 12 months after randomization

    Multiple pregnancy is defined as the detection of two or more gestational sacs or positive heart beats by ultrasound.

  27. Miscarriage rate

    Time frame: At 24 weeks of gestation; At 12 months after randomization

    Miscarriage refers to the loss of an intra-uterine pregnancy before 24 weeks of gestation.

  28. Gestational diabetes mellitus

    Time frame: At 24-28 weeks of gestation

    Abnormal OGTT test

  29. Hypertensive disorders of pregnancy

    Time frame: From 20 weeks of gestation up to at birth

    The hypertensive disorders of pregnancy include gestational hypertension, chronic hypertension, pre-eclampsia, chronic hypertension with preeclampsia, eclampsia and HELLP syndrome.

  30. Antepartum haemorrhage

    Time frame: From 20 weeks of gestation up to at birth

    Vaginal bleeding caused by placenta previa, placental implantation, or unknown reasons in mid or late pregnancy.

  31. Thrombotic diseases

    Time frame: From 20 weeks of gestation up to 4-6 weeks after birth

    If the participant experiences clinical symptoms such as lower limb pain, chest pain, hemoptysis, etc., and there is a high suspicion of thrombotic disease in clinical practice, confirmation will be made through examinations such as vascular ultrasound and CT angiography.

  32. Gestational age at delivery

    Time frame: At birth

  33. Preterm birth

    Time frame: At birth

    Pregnancy terminates after 28 weeks and before 37 weeks of gestation.

  34. Spontaneous preterm birth

    Time frame: At birth

    Termination of pregnancy due to premature rupture of membranes or spontaneous uterine contractions between 28 to 37 weeks of gestation.

  35. Iatrogenic preterm birth

    Time frame: At birth

    Termination of pregnancy due to iatrogenic factors between 28 to 37 weeks of gestation.

  36. Birth weight

    Time frame: At birth

    Weight of newborn, classified as very low birth weight (<1500g), low birth weight (1500-2500g), macrosomia (>4000g).

  37. Small for gestational age

    Time frame: At birth

    Birth weight below the 10th percentile for gestational age.

  38. Large for gestational age

    Time frame: At birth

    Birth weight above the 90th percentile for gestational age.

  39. Birth defect / Congenital anomaly

    Time frame: At birth; At 4-6 weeks after birth

    Any birth defect or congenital anomaly will be included.

  40. NICU admission

    Time frame: At 4-6 weeks after birth

    The admittance of the newborn to NICU.

  41. Perinatal mortality

    Time frame: At 4-6 weeks after birth

    Fetal or neonatal death occurring after 28 weeks of gestation, during delivery, or within 7 days after birth.

  42. Neonatal mortality

    Time frame: At 4-6 weeks after birth

    Death of a live born baby within 28 days of birth.

Study contacts

Contact information is provided by the study sponsor or research team.

Min Jin, PhD

CONTACT

[email protected]

+86-15925602121

Sponsors and collaborators

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other

Collaborators

  • Beijing Obstetrics and Gynecology Hospital
  • Huangshi Central Hospital
  • Jiaxing Maternity and Child Health Care Hospital
  • Ningbo Women & Children's Hospital
  • Renmin Hospital of Wuhan University
  • Xiangyang Central Hospital

Registry information

Official study title

Intracytoplasmic Sperm Injection (ICSI) Versus Conventional in Vitro Fertilization (IVF) in Couples With Unexplained Infertility: a Multicenter, Open-label, Parallel-group, Randomized Controlled Trial

Acronym: ICSI/IVF-UI

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Dec 19, 2025
Registry last updated
Dec 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.